Akili Inc
AKLI
$0.25
Closing
▲3.77%
1D
▼-47.14%
YTD
Market cap
$19.49M
52 week high
$1.67
52 week low
$0.19
Volume
7,613
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$19.49M
Analysts' Rating
BUY
Price Target (Mean)
4
Total Analysts
3
P/E
Operating Margin
-2624.79%
Beta
Revenue Growth (Annual)
-39.96%
52 week high
$1.67
52 week low
$0.19
Div. Yield
%
EPS Annual Growth
33.33
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Akili, Inc. (Akili) is a digital medicine company engaged in the development of cognitive treatments through technologies. The Company is focused on developing and commercializing technologies designed to directly target the physiology of the brain. The Company’s software-based medicine is designed to directly target brain function and is delivered through engaging consumer entertainment. Akili’s platform is powered by proprietary therapeutic engines designed to target cognitive impairment at its source in the brain. The Company’s products include EndeavorRx, Selective Stimulus Management Engine (SSME), Body Brain Trainer (BBT) and Spatial Navigation (SNAV) Engine. EndeavorRx product is measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. SSME is specifically engineered to target and activate the systems in the brain that play a key role in attention function.
